IDSA Updated Covid-19 Guideline now supports the use of convalescent plasma in ambulatory patients with mild to moderate COVID-19 at high risk for progression to severe disease.

IDSA Guidelines on the Treatment and Management of Patients with COVID-19 – Infectious Diseases Society of America

Related: [Preprint] RCT: In symptomatic adults above 18 years positive for SARS-CoV-2, early outpatient treatment with high-titer convalescent plasma significantly reduced hospitalizations.

Commentary on Twitter

Update Alert: Revised recommendation on the use of #convalescentplasma in ambulatory patients w/ COVID-19 at high risk of progression to severe disease w/ no other treatment options.

?: https://t.co/YRCxtdilXT#COVID19Guidelines @JGPharmD @adarsh_bhimraj @RMKGandhi @ShohamTxID pic.twitter.com/KpXnywH362

— IDSA (@IDSAInfo) February 8, 2022